News

First preclinical evidence of the potent antitumor effect of DIMATE against glioblastoma

Glioblastoma (GBM) is the most common and aggressive type of brain tumour in adults. Classified as a grade 4 glioma, GBM is renowned for resistance to radio- and chemo-therapy and is generally lethal within 12 months.

In the press: Interview in Capital

Advanced BioDesign against TNBC

THERALDIN®TNBC, a multidisciplinary research program coordinated by Advanced Biodesign,  aims to elucidate the role of ALDH in triple-negative breast cancer (TNBC). In this context, a DIMATE-based therapy that is currently under investigation holds promise in the treatment of this aggressive disease.

Advanced BioDesign welcomes Prof. Pierre Tambourin to its scientific advisory board

A world-renowned expert in molecular oncology research, Prof. Tambourin will assist Advanced BioDesign’s teams in developing DIMATE, which has the potential to become a major new targeted therapy in the treatment of resistant cancers.

In the press: Ismail CEYLAN Interview in SMALL is SMART

Ismail CEYLAN, CEO of Advanced BioDesign was interviewed by Jean-Marc Sylvestre in the show SMALL is SMART by B SMART.

Advanced BioDesign and Luxembourg Institute of Health (LIH) join forces to explore new therapeutic strategies for overcoming tumor resistance

Lyon, France, and Luxembourg, July 1, 2020 – Advanced BioDesign, a French biotechnology company specializing in the development of innovative therapies for resistant forms of cancer, and the Luxembourg Institute of Health (LIH), a public biomedical research institute, announce today a partnership to embark on a collaborative research program.

Advanced BioDesign publishes its study in Non-Smal Cell Lung Cancer (NSCLC) in Oncogene

Study shows for first time benefit of its active compound DIMATE in overcoming drug resistance in NSCLC

Lyon, France, May 12, 2020 – Advanced BioDesign, dedicated to developing novel therapies against resistant cancers, today announces promising results using its dual inhibitor DIMATE against an original therapeutic target, the ALDH enzymes family, in pulmonary cancer. 

Advanced BioDesign raises additional €9 million from Xerys Funds

Lyon, France, February 25, 2020 – Advanced BioDesign, dedicated to developing new therapies for overcoming tumor resistant cancers, announces today that it has raised an additional €9M ($9.8M) financing from Xerys Funds to pursue its clinical development.

Advanced BioDesign joins ENHPATHY consortium to increase its knowledge in genetic alterations in hematologic cancers

Lyon, France, January 21, 2019 - Consortium gathers 27 organizations from 11 countries to work on enhanceropathies; will receive €4M from European Commission over next four years Lyon, France, January 21, 2020 – Advanced BioDesign, a French pre-clinical stage biotechnology company focused on the development of a new treatment against resistant cancers, today announces it has teamed up with 27 European academic and industrial organizations from 11 countries to form the multidisciplinary science consortium, ENHPATHY.

17th January 2020

Advanced BioDesign Present Preclinical Result at 61st ASH Annual Meeting

Advanced BioDesign has presented a poster at the 61^st American Society of Hematology (ASH) Annual Meeting with their rational on its lead compound ABD-3001, as a treatment of patients with refractory or relapse Acute Myeloid Leukemia (r/r AML).

21st October 2019

In the press: Biotech Finances introduces Advanced BioDesign

Advanced BioDesign is honored in the French Journal - Biotech Finances - for the development of its first-in-class ALDH inhibitor in cancer targeted therapy. 

10 September 2019

Advanced BioDesign, member of ENHPATHY consortium

5 July 2019

Advanced BioDesign and Marseille’s Hospital allied in research against blood cancer